The performance of pharmaceutical enterprises continued to increase, and the export volume began to increase

[industry trends of pharmaceutical Station] the pharmaceutical products are in a connecting position in the pharmaceutical industry chain, and play an important role in supporting the research and development of new drugs and promoting the industrialization of new drugs In recent years, with the continuous environmental protection and high pressure, the brand shuffling of API industry is accelerated, and the trend of upgrading to preparation is highlighted In addition, in terms of policies, the 13th five year plan guide for the development of pharmaceutical industry issued by the Ministry of industry and information technology of the people's Republic of China proposes to implement the strategic development goal of pharmaceutical internationalization, comprehensively improve the scale, proportion and product added value of China's pharmaceutical exports, and focus on expanding the markets of developed countries and emerging pharmaceutical markets At the same time, we will support the construction of a batch of high standard preparation production bases, which have passed the GMP certification in Europe and the United States We will encourage the international registration of new drugs, chemical generics, traditional Chinese medicine and biological analogues, and bring about the listing of 3-5 new drugs and more than 200 chemical generics on the markets of developed countries These favorable policies will accelerate the internationalization of preparations in China In addition, in 2019, with the continuous promotion of consistency evaluation and the implementation of "4 + 7" volume procurement, the performance of a batch of enterprises producing preparations continued to increase by a long margin, and the export began to be large Puli pharmaceutical reported that Puli pharmaceutical's injection with the European and American market leading experience, earlier benefit from consistency evaluation Among them, the special dosage form of oral general medicine is more respected by dealers under the background of 4 + 7 policy, and the sales volume and gross profit increase at the same time The industry forecasts that the company's net profit in 2019-2021 will be 349, 515 and 713 million yuan respectively, with an increase rate of 93%, 47% and 39% According to the public data of tisley, in 2018, the revenue of tisley chemicals increased by 15% to 1.5 billion yuan year on year Among them, sales volume of Shuilinjia increased nearly 5% year on year, and sales volume of temozolomide increased about 10% year on year It is worth noting that temozolomide of Tianshili passed the consistency evaluation in March, 19, and the import substitution is expected to be accelerated Pulo pharmaceutical has benefited from the optimization of external environment and the improvement of internal efficiency, and it has entered a new and rapid development period since 2018 The operation efficiency is improved quarter by quarter, and both internal and external driving forces promote the company's growth Among them, the prosperity of API industry is expected to maintain a high level, and cdmo and preparation industry will open a large space It is estimated that during 2019-2021, the company's net profit will be 513, 655 and 854 million yuan respectively In general, China's pharmaceutical industry has a good prospect, and the pharmaceutical companies with extraction layout are expected to get good benefits in the next few years However, the industry points out that compared with developed countries, the internationalization level of Chinese preparations is still weak On the one hand, the pharmaceutical technology level of China's pharmaceutical industry has not formed systematization and modularization, and the international quality production capacity and quality control system are not available Therefore, there are certain difficulties in the export of pharmaceutical products, which can only be achieved by a few enterprises with strength On the other hand, in recent years, the labor cost has increased, the R & D cost required by pharmaceutical enterprises has increased year by year, and the capital pressure is great And the current equipment involves software system, which needs to be adjusted later to be used by enterprises In addition, the R & D cycle of preparations is relatively long, and many enterprises lack motivation and enthusiasm for R & D, which also affects the improvement of the internationalization level of preparations in China Therefore, it is necessary to start from the efforts of all sectors of society to move to a higher stage in China's pharmaceutical industry Relying on the strength of the enterprise itself, it is difficult to promote the level of the whole industry, and there are some difficulties in export In terms of policy, pharmaceutical enterprises should be given more support, and the level of pharmaceutical technology needs to be further improved.